ONKURE THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
ONKURE THERAPEUTICS, INC. (OKUR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $14.88 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- ONKURE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $11.02, a 75.05% decline year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $44.16.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $42.88, a 98.33% increase from fiscal 2024.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $21.62.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.88 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $11.02 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | $42.88 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $42.88 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $37.30 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $44.16 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $21.62 10-K · filed 2025-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |